PRA Health Sciences and Deep Lens Announce Partnership for Precision Cancer Trials
PRA Health Sciences, Inc. and Deep Lens, Inc., have announced a new strategic relationship aiming to accelerate patient access and recruitment for oncology clinical trials. The relationship brings together technologies that improve the identification, screening, and matching of cancer patients to precision-based clinical oncology trials on a global basis, with the combined solution being deployed to Microsoft Azure.
Deep Lens’ VIPER patient screening platform is a technology deployed by cancer centers, integrated delivery networks, and community oncology networks to identify and match oncology patients to clinical trials who would have otherwise fallen through the cracks and missed the opportunity to enroll. The differentiated technology and services model allows Deep Lens to deploy its software at cancer centers and site networks on a global basis, free of charge, to better give patients access to the therapies they need and deserve.
The combined effort between PRA and Deep Lens brings a critical advancement to clinical trial matching to more efficiently connect eligible patients with potential clinical trials by leveraging artificial intelligence and machine learning via the VIPER platform.
To learn more, read the full release, here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FSP Outsourcing in Clinical Research: Trends and Opportunities
June 9th 2025When drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.
